These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31082860)

  • 1. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
    Meireles MV; Pascom ARP; Duarte EC; McFarland W
    AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT
    AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
    N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
    Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
    Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
    Dorward J; Sookrajh Y; Khubone T; van der Molen J; Govender R; Phakathi S; Lewis L; Bottomley C; Maraj M; Lessells RJ; Naidoo K; Butler CC; Van Heerden R; Garrett N
    Lancet HIV; 2023 May; 10(5):e284-e294. PubMed ID: 37001536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
    AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
    Semengue ENJ; Fokam J; Etame NK; Molimbou E; Chenwi CA; Takou D; Mossiang L; Meledie AP; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Djupsa Ndjeyep SC; Abba A; Kengni AMN; Tommo Tchouaket MC; Bouba NP; Billong SC; Sosso SM; Colizzi V; Perno CF; Kouanfack C; Zoung-Kanyi Bissek AC; Eben-Moussi E; Santoro MM; Ceccherini-Silberstein F; Ndjolo A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
    Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
    Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
    Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L
    AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens.
    Silva GJD; Mendicino CCP; Pádua CAM; Tupinambás U
    Einstein (Sao Paulo); 2023; 21():eAO0156. PubMed ID: 37255057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cumulative viraemia following treatment initiation with different antiretroviral regimens: a real-life study in Brazil.
    Pascom AR; Pinho RE; Rick F; Veras NM; Perini FB; Meireles MV; Pereira GF; Benzaken AS; Avelino-Silva VI
    J Int AIDS Soc; 2019 Nov; 22(11):e25397. PubMed ID: 31743620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.
    Devendra A; Kohler M; Letsika M; Khooa H; Motaboli L; Lerotholi M; Tschumi N; Labhardt ND; Brown JA
    AIDS; 2024 Jun; 38(7):1013-1023. PubMed ID: 38381717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.